Sugi Predict

Sugi Predict / Compounds / SCHEMBL1395347

SCHEMBL1395347

SCHEMBL1395347

Nc1nc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.77

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 5/20 0.77
▸ CYP1A2 P05177 5/20 0.77
▸ CYP1B1 Q16678 5/20 0.77
▸ DCPS Q96C86 1/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ ATM Q13315 1/20 0.61
▸ ADORA2A P29274 4/20 0.56
▸ ADORA1 P30542 4/20 0.54
▸ ADORA3 P0DMS8 2/20 0.54
▸ ADORA2B P29275 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ ABCG2 Q9UNQ0 3/20 0.53
▸ PDE5A O76074 2/20 0.51
▸ ACP1 P24666 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29593101 1.00 CYP1A1 (0.77) CYP1A1CYP1A2CYP1B1DCPSMEN1
Hydrochloric Acid SCHEMBL29281621 0.98 CYP1A1 (0.77) CYP1A1CYP1A2CYP1B1DCPSMEN1
SCHEMBL14529287 0.96 CYP1A1 (0.77) CYP1A1CYP1A2CYP1B1DCPSMEN1
Pyridine SCHEMBL27700469 0.91 CYP1A2 (0.66) CYP1A1CYP1A2CYP1B1DCPSMEN1
SCHEMBL12443214 0.90 CYP1A2 (0.75) CYP1A1CYP1A2CYP1B1DCPSMEN1
SCHEMBL30843880 0.89 CYP1A1 (0.68) CYP1A1CYP1A2CYP1B1DCPSMEN1
SCHEMBL11861155 0.89 CYP1A1 (0.68) CYP1A1CYP1A2CYP1B1DCPSMEN1
SCHEMBL28773619 0.87 CYP1A1 (0.71) CYP1A1CYP1A2CYP1B1DCPSMEN1
Hydrochloric Acid SCHEMBL11870267 0.87 CYP1A1 (0.69) CYP1A1CYP1A2CYP1B1DCPSMEN1
SCHEMBL28197250 0.87 CYP1A1 (0.71) CYP1A1CYP1A2CYP1B1DCPSMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924190-A 2-Phenyl-4-amino quinazoline compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 重庆医科大学 2024-04-26 — — CN claimed
CN-106117182-B Quinazoline-N- phenethyl tetrahydroisoquinolicompounds compounds and its preparation method and application 中国药科大学 2019-08-30 — — CN claimed
CN-102784146-A Medicinal use of N-phenylquinazolinyl-4-amine derivatives UNIV FUDAN 2012-11-21 — — CN claimed
CN-117924190-A 2-Phenyl-4-amino quinazoline compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 重庆医科大学 2024-04-26 — — CN disclosed
CN-117924190-A 2-Phenyl-4-amino quinazoline compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 重庆医科大学 2024-04-26 — — CN disclosed
CN-117924190-A 2-Phenyl-4-amino quinazoline compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 重庆医科大学 2024-04-26 — — CN disclosed
CN-114591251-B Chiral aminoquinazoline compound, and preparation method and application thereof 华南理工大学 2023-06-20 — — CN disclosed
CN-114591251-A Chiral aminoquinazoline compound and preparation method and application thereof 华南理工大学 2022-06-07 — — CN disclosed
EP-3428149-B1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO LTD (KR) 2021-07-28 — — EP disclosed
EP-3301097-B1 [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) SAMSUNG DISPLAY CO LTD (KR) 2020-08-19 — — EP disclosed
EP-3693372-A1 BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) Samsung Display Co., Ltd. (KR) 2020-08-12 — — EP disclosed
CN-1993349-A Quinazoline derivatives as ERBB receptor tyrosine kinases ASTRAZENECA AB (SE) 2007-07-04 — — CN disclosed
EP-1318814-B1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2007-05-30 — — EP disclosed
CN-1906178-A Quinazoline derivatives ASTRAZENECA AB (SE) 2007-01-31 — — CN disclosed
CN-1882572-A Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2006-12-20 — — CN disclosed
EP-1730125-A2 SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-12-13 — — EP disclosed
US-20050239836-A1 Substituted hydroxyethylamine aspartyl protease inhibitors ELAN PHARMACEUTICALS, INC. 2005-10-27 — — US disclosed
WO-2005087751-A2 SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-09-22 — — WO disclosed
US-20050130251-A1 Reagent for determination of hydrogen peroxide KYOWA MEDEX CO., LTD. (JP) 2005-06-16 — — US disclosed
EP-1424554-A1 REAGENT FOR DETERMINING HYDROGEN PEROXIDE KYOWA MEDEX CO., LTD. (JP) 2004-06-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239836-A1 Substituted hydroxyethylamine aspartyl protease inhibitors DNPEP, MME, ANPEP CYP1A1 2753/4885CYP1A2 3197/4885CYP1B1 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.